These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9384230)

  • 1. Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys.
    Suzuki K; Sakai Y; Hisamichi N; Taniuchi Y; Sato K; Terazaki C; Kaku S; Kawasaki T; Yano S; Inagaki O; Masuho Y
    Eur J Pharmacol; 1997 Oct; 336(2-3):169-76. PubMed ID: 9384230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
    Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.
    Harder S; Kirchmaier CM; Krzywanek HJ; Westrup D; Bae JW; Breddin HK
    Circulation; 1999 Sep; 100(11):1175-81. PubMed ID: 10484537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
    Kawasaki T; Sato K; Suzuki K; Sakai Y; Taniuchi Y; Kaku S; Yano S; Inagaki O; Tomioka K; Masuho Y; Yanagisawa I; Takenaka T
    Thromb Haemost; 1998 Mar; 79(3):663-7. PubMed ID: 9531059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Yano S; Kawasaki T; Sakai Y; Suzuki K; Kawamura K; Masuho Y; Satoh N; Takenaka T; Landolfi NF; Co MS
    Gen Pharmacol; 1996 Apr; 27(3):435-9. PubMed ID: 8723521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
    Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function.
    Bhattacharya S; Jordan R; Machin S; Senior R; Mackie I; Smith CR; Schaible TF; Weisman HF; Lahiri A
    Cardiovasc Drugs Ther; 1995 Oct; 9(5):665-75. PubMed ID: 8573549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
    Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
    Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
    Graff J; Klinkhardt U; Westrup D; Kirchmaier CM; Breddin HK; Harder S
    Br J Clin Pharmacol; 2003 Sep; 56(3):321-6. PubMed ID: 12919181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys.
    Kageyama S; Yamamoto H; Nakazawa H; Matsushita J; Kouyama T; Gonsho A; Ikeda Y; Yoshimoto R
    Arterioscler Thromb Vasc Biol; 2002 Jan; 22(1):187-92. PubMed ID: 11788481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis.
    Kageyama S; Matsushita J; Yamamoto H
    Eur J Pharmacol; 2002 May; 443(1-3):143-9. PubMed ID: 12044804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs.
    Kageyama S; Yamamoto H; Nakazawa H; Yoshimoto R
    Thromb Res; 2001 Mar; 101(5):395-404. PubMed ID: 11297756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
    Mascelli MA; Lance ET; Damaraju L; Wagner CL; Weisman HF; Jordan RE
    Circulation; 1998 May; 97(17):1680-8. PubMed ID: 9591761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.